MICHAEL PLOTNICK, M.D.
GLOBAL MEDICAL AFFAIRS
Michael Plotnick, M.D. is Vice President, Global Medical Affairs for the Immunology Global Commercial Strategy Organization of Janssen Global Services. In this role, he leads a team of Global Medical Affairs leaders responsible for the clinical-commercial optimization of product development and life cycle management strategies and plans for both approved products, and products in clinical development for the industry-leading Janssen Immunology portfolio.
Michael joined Janssen in 2004 where he served as the Medical Director for the Dermatology disease area stronghold supporting the launch of REMICADE® (infliximab) for psoriatic arthritis and psoriasis in the United States. Most recently, Michael served as the Global Medical Affairs Leader for STELARA® (ustekinumab) and TREMFYA® (guselkumab).
Prior to joining Janssen, Michael served on the medical faculty of the University of Pennsylvania School of Medicine for 11 years. He was an attending physician at the Hospital of the University of Pennsylvania and Philadelphia Veterans Administration Hospital and ran a National Institutes of Health-funded laboratory studying the structure-function, kinetics and molecular mechanisms of serine protease inhibitors and their interaction with serine proteases.
Michael earned his M.D. from the New York University School of Medicine in New York City. He completed his residency training in Internal Medicine at Columbia Presbyterian Medical Center in New York City, and clinical and research fellowship training in Pulmonary and Critical Care Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania.